Dysembryoplastic neuroepithelial tumor (DNT) Pediatric Research and Clinical Trials

LIke ThisLIke ThisLIke ThisLIke ThisLIke This

Contact the Glioma Program

A hopeful future

Treatment for brain tumors in children has progressed tremendously in the last decade:

  • New tools are being used to help doctors diagnose tumors sooner and with more accuracy.
  • Radiation therapy and chemotherapy are increasingly targeting tumors more accurately and effectively while keeping clear of healthy brain cells and tissue.
  • A successful new surgical technique is the intra-operative MRI, which gives surgeons a three-dimensional picture of the tumor so they can remove the cancer while leaving other parts of the brain relatively untouched.

Research & clinical trials

Our program offers unique access to a range of clinical trials in which your child can receive the newest brain tumor treatments. Through this research, our physicians work to improve current therapeutic approaches and outcomes for many hard-to-treat pediatric brain tumors.

Dana-Farber/Boston Children’s Cancer and Blood Disorders Center oversees New England’s most active pediatric oncology clinical research program; it provides access to unique clinical trials for patients with newly diagnosed, relapsed or refractory brain tumors. We are:

  • New England’s Phase I Children’s Oncology Group referral center, a Pediatric Oncology Experimental Therapeutics Investigator Consortium member (POETIC), and a founding institution of the Pediatric Brain Tumor Consortium. We are also members of the Pediatric Blood and Marrow Transplant Consortium (PBMTC)
  • skilled at improving current therapeutic approaches and outcomes of hard to treat pediatric brain tumors.

Rapidly translating scientific discoveries to the bedside is a major focus of the program. Members of our brain tumor team:

  • played a key role in the identification and application of anti-angiogenic treatments for pediatric brain tumors
  • launched new studies investigating gene profiling of patients’ tumors and the development of personalized treatment approaches
  • pioneered the development of new treatments for specific highly malignant tumors such as ATRT
  • are developing tissue registries to better classify and treat certain types of brain tumors
We are grateful to have been ranked #1 on U.S. News & World Report's list of the best children's hospitals in the nation for the third year in a row, an honor we could not have achieved without the patients and families who inspire us to do our very best for them. Thanks to you, Boston Children's is a place where we can write the greatest children's stories ever told.”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital
300 Longwood Avenue, Boston, MA 02115
For Patients: 617-355-6000
For Referring Providers: 844-BCH-PEDS | 844-224-7337